COTA and Sanofi collaborate to accelerate cancer trials using real-world data and AI

How will FDA regulate psychedelics?

FDA has been taking a look at psychedelics as a potential treatment for psychiatric and substance abuse disorders, recently publishing a final guidance for drug sponsors conducting clinical trials of psychedelics, including psilocybin, LSD, and MDMA.

July 22, 2026

Podcast The Directors

The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the way
Knudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long”

The United States has a translation problem. Scientific breakthroughs in oncology are accelerating, but clinical trial infrastructure hasn’t kept pace.

July 17, 2026

Vol.52 No.28

By Paul Goldberg and Claire Marie Porter

Clinical Roundup

Lenalidomide maintenance may end after two years for patients with MM, phase III trial finds

For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance has long been standard of care, despite limited evidence to guide the optimal duration of treatment.

July 17, 2026

Vol.52 No.28

Clinical Roundup

Jemperli achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer, phase II study finds

AZUR-1 trial, a single arm trial of Jemperli (dostarlimab) in patients with stage 2/3 mismatch repair deficient/microsatellite instability-high locally advanced rectal cancer, met its primary objective, showing a meaningful and sustained clinical complete response rate at 12 months.

July 17, 2026

Vol.52 No.28

Clinical Roundup

Ris-Rez improves overall survival in SCLC, phase III trial finds

ARTEMIS-008, a phase III trial evaluating Ris-Rez (risvutatug rezetecan) in patients with advanced or relapsed small-cell lung cancer, met its primary endpoint of overall survival.

July 17, 2026

Vol.52 No.28

Clinical Trials & Tribulations

The challenge of making the move from conversational AI to autonomous scientific discovery
Advancing from level II to level III AI agents in precision medicine

Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research.

July 10, 2026

Vol.52 No.27

By Enrique Velazquez-Villarreal

COTA and Sanofi collaborate to accelerate cancer trials using real-world data and AI

YOU MAY BE INTERESTED IN

How will FDA regulate psychedelics?

The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the way
Knudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long”

Lenalidomide maintenance may end after two years for patients with MM, phase III trial finds

Jemperli achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer, phase II study finds

Ris-Rez improves overall survival in SCLC, phase III trial finds

The challenge of making the move from conversational AI to autonomous scientific discovery
Advancing from level II to level III AI agents in precision medicine

Renew today!

Subscriber content

Never miss an issue!

Login

COTA and Sanofi collaborate to accelerate cancer trials using real-world data and AI

YOU MAY BE INTERESTED IN

How will FDA regulate psychedelics?

The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the wayKnudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long”

Lenalidomide maintenance may end after two years for patients with MM, phase III trial finds

Jemperli achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer, phase II study finds

Ris-Rez improves overall survival in SCLC, phase III trial finds

The challenge of making the move from conversational AI to autonomous scientific discoveryAdvancing from level II to level III AI agents in precision medicine

Never miss an issue!

Login

The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the way
Knudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long”

The challenge of making the move from conversational AI to autonomous scientific discovery
Advancing from level II to level III AI agents in precision medicine